ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,768,771 | -33.9% | 696,171 | 0.0% | 1.46% | +15.2% |
| Q2 2023 | $7,219,293 | +28.2% | 696,171 | 0.0% | 1.27% | +8.8% |
| Q1 2023 | $5,632,023 | -48.6% | 696,171 | 0.0% | 1.16% | -50.7% |
| Q4 2022 | $10,964,693 | +0.1% | 696,171 | 0.0% | 2.36% | -7.6% |
| Q3 2022 | $10,958,000 | +12.7% | 696,171 | 0.0% | 2.56% | -1.4% |
| Q2 2022 | $9,719,000 | -29.0% | 696,171 | -12.3% | 2.59% | -24.8% |
| Q1 2022 | $13,692,000 | +18.6% | 794,171 | 0.0% | 3.45% | +53.9% |
| Q4 2021 | $11,547,000 | -19.2% | 794,171 | 0.0% | 2.24% | -0.1% |
| Q3 2021 | $14,295,000 | +2.5% | 794,171 | 0.0% | 2.24% | +30.3% |
| Q2 2021 | $13,946,000 | -45.9% | 794,171 | -22.3% | 1.72% | -63.8% |
| Q1 2021 | $25,770,000 | +192.3% | 1,022,612 | -25.0% | 4.75% | +435.9% |
| Q4 2020 | $8,816,000 | +59.3% | 1,362,612 | -36.7% | 0.89% | -42.6% |
| Q3 2020 | $5,534,000 | +31.0% | 2,153,265 | -17.4% | 1.54% | +13.6% |
| Q2 2020 | $4,225,000 | +55.8% | 2,608,117 | 0.0% | 1.36% | -12.9% |
| Q1 2020 | $2,712,000 | – | 2,608,117 | – | 1.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Endurant Capital Management LP | 1,769,785 | $1,911,000 | 0.69% |
| Telemetry Investments, L.L.C. | 214,593 | $232,000 | 0.67% |
| Aisling Capital Management LP | 634,455 | $685,000 | 0.36% |
| Broadfin Capital, LLC | 1,620,000 | $1,750,000 | 0.32% |
| MFN Partners Management, LP | 1,500,000 | $1,620,000 | 0.24% |
| Sofinnova Investments, Inc. | 1,911,573 | $2,064,000 | 0.19% |
| Rock Springs Capital Management LP | 2,974,754 | $3,213,000 | 0.13% |
| Alambic Investment Management, L.P. | 150,636 | $163,000 | 0.12% |
| Cormorant Asset Management, LP | 250,000 | $270,000 | 0.02% |
| Man Group plc | 3,734,793 | $4,034,000 | 0.02% |